COMP <GO>
XERS vs UNH // GROSS PROFIT MARGIN
Xeris Biopharma Holdings Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: XERS 4
— UNH 6
■ METRIC PARITY
LAST: $10.75 (+1.03%) • MKT CAP: $1.96B
gross-margins
—
LAST: $410.91 (+0.94%) • MKT CAP: $368.83B
gross-margins
88.57%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (XERS VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | XERS | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | — | 88.57% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 16.00% | 11.47% | +4.53 | XERS | /roic <GO> |
| EV/EBITDA & P/E Valuation | 83.1x | 16.4x | +66.65 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 1.46% | 6.48% | -5.02 | UNH | /fcf-yield <GO> |
| Operating Margin | 8.50% | 4.82% | +3.68 | XERS | /operating-margins <GO> |
| Net Profit Margin | 0.20% | 3.14% | -2.94 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | 43.70% | 6.46% | +37.24 | XERS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.11 | 3.12 | -1.01 | UNH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 60.0 | 59.2 | +0.82 | XERS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 17.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.96B | $368.83B | -$366.87B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | XERS REV | UNH REV | XERS GROSS % | UNH GROSS % | XERS FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $291.8M | $447.57B | — | 88.7% | $28.6M | $16.07B |
| FY 2024 | $203.1M | $400.28B | — | 88.3% | -$37.0M | $20.70B |
| FY 2023 | $163.9M | $371.62B | — | 89.6% | -$47.0M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
XERS // BETA —
UNH // BETA 0.33